Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 8, 2010, Pages 1792-1798

  Lin, Sheng Hsiang ^a   Liao, Wan Hsiu ^a   Lai, Chih Cheng ^b   Liao, Chun Hsing ^c   Tan, Che Kim ^d   Wang, Cheng Yi ^b   Huang, Yu Tsung ^e   Hsueh, Po Ren ^e  

^a Taipei County Hospital   (Taiwan)

^b CARDINAL TIEN HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Minimum inhibitory concentration; Outcome; Salvage; Vancomycin

Indexed keywords

AMINOGLYCOSIDE; LINEZOLID; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PERSISTENT INFECTION; RISK FACTOR; TAIWAN; TERTIARY HEALTH CARE; ADOLESCENT; BACTEREMIA; HOSPITAL; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PROGNOSIS; STAPHYLOCOCCUS INFECTION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; FEMALE; HOSPITALS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROGNOSIS; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; TAIWAN; VANCOMYCIN; YOUNG ADULT;

EID: 77954699475     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq188     Document Type: Article

References (30)

1. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46: S344-9.
2. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
3. Kim SH, Park WB, Lee KD et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis 2003; 37: 794-9.
4. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 2007; 44: 1543-8.
5. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
6. Hawkins C, Huang J, Jin N et al. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 2007; 167: 1861-7.
7. Khatib R, Johnson LB, Sharma M et al. Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand J Infect Dis 2009; 41:4-9.
8. Khosrovaneh A, Riederer K, Saeed S et al. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2004; 38: 1328-30.
9. Howden BP, Johnson PD, Ward PB et al. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50: 3039-47.
10. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-80.
11. Jang HC, Kim SH, Kim KH et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009; 49: 395-401.
12. Hageman JC, Liedtke LA, Sunenshine RH et al. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin Infect Dis 2006; 43: e42-5.
13. Fang CT, Shau WY, Hsueh PR et al. Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome. J Antimicrob Chemother 2006; 57: 511-9.
14. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests-Ninth Edition: Approved Standard M2-A9. Wayne, PA, USA: CLSI, 2006.
15. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. Wayne, PA, USA: CLSI, 2009.
16. CDC. CA-MRSA Clinician FAQs: CDC Infection Control in Healthcare. Modified 3 February 2005. http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca_clinicians.html (24 July 2009, date last accessed).
17. McCabe WR, Jackson GG. Gram-negative bacteremia. Arch Intern Med 1962; 110: 847-64.
18. Liao CH, Lai CC, Chen SY et al. Strain relatedness of meticillin-resistant Staphylococcus aureus isolates recovered from patients with repeated bacteraemia. Clin Microbiol Infect 2010; 16: 463-9.
19. Li JS, Sexton DJ, Mick N et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633-8.
20. Hsueh PR, Teng LJ, Chen WH et al. Increasing prevalence of methicillin-resistant Staphylococcus aureus causing nosocomial infections at a university hospital in Taiwan from 1986 to 2001. Antimicrob Agents Chemother 2004; 48: 1361-4.
21. Calfee DP, Salgado CD, Classen D et al. Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29: S62-80.
22. Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-20.
23. Moise-Broder PA, Sakoulas G, Eliopoulos GM et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700-5.
24. Musta AC, Riederer K, Shemes S et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009; 47: 1640-4.
25. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200.
26. Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-8.
27. Cremieux AC, Maziere B, Vallois JM et al. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis 1989; 159: 938-44.
28. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006; 42: S40-50.
29. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005; 56: 923-9.
30. Moise PA, Forrest A, Birmingham MC et al. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002; 50: 1017-26.